Could COVID-19 'Inflammatory Signature' Predict Disease Cour
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
Get authentic, real-time news that helps you fight COVID-19 better.
Install PlexusMD App for doctors. It's free.
An inflammatory signature may hold a clue to predicting both COVID-19 severity and poor clinical outcomes, researchers found.

Several studies have revealed that the hyper-inflammatory response induced SARS-CoV-2 is a major cause of disease severity and death. However, predictive biomarkers of pathogenic inflammation to help guide targetable immune pathways are critically lacking.

Researchers implemented a rapid multiplex cytokine assay to measure serum interleukin (IL)-6, IL-8, tumor necrosis factor (TNF)-alpha and IL-1 beta in hospitalized patients with COVID-19 upon admission.

Patients (n=1,484) were followed up to 41 d after admission (median, 8 d), and clinical information, laboratory test results and patient outcomes were collected.

Researchers found that high serum IL-6, IL-8 and TNF-alpha levels at the time of hospitalization were strong and independent predictors of patient survival.

Notably, when adjusting for disease severity, common laboratory inflammation markers, hypoxia and other vitals, demographics, and a range of comorbidities, IL-6 and TNF-alpha serum levels remained independent and significant predictors of disease severity and death. These findings were validated in a second cohort of patients.

Researchers propose that serum IL-6 and TNF-alpha levels should be considered in the management and treatment of patients with COVID-19 to stratify prospective clinical trials, guide resource allocation and inform therapeutic options.

Dr. T●●●●z H●●●●●●i and 1 others like this1 share